{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Txt":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE327nnn/GSE327102/suppl/GSE327102_gene_counts_GEOv2.txt.gz"],"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE327nnn/GSE327102/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE327102"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Transcriptomic profiling of peripheral blood from myasthenia gravis patients before and after efgartigimod treatment","description":"Neonatal Fc receptor (FcRn) blockade with efgartigimod is an effective therapy for myasthenia gravis (MG), yet the molecular changes beyond IgG clearance remain incompletely understood. In this study, paired peripheral blood samples collected at baseline and week 4 after efgartigimod treatment underwent bulk RNA-seq profiling to investigate transcriptomic remodeling associated with FcRn inhibition in MG. Raw sequencing data have been deposited in the National Genomics Data Center (NGDC) under accession subHRA027638.","dates":{"publication":"2026/04/08"},"accession":"GSE327102","cross_references":{"GSM":["GSM9648417","GSM9648406","GSM9648418","GSM9648407","GSM9648419","GSM9648408","GSM9648409","GSM9648410","GSM9648411","GSM9648400","GSM9648401","GSM9648412","GSM9648413","GSM9648402","GSM9648414","GSM9648403","GSM9648404","GSM9648415","GSM9648416","GSM9648405"],"GPL":["24676"],"GSE":["327102"],"taxon":["Homo sapiens"]}}